UBS Group Reiterates CHF 237 Price Target for Roche (ROG)

Roche (VTX:ROG) has been given a CHF 237 price objective by stock analysts at UBS Group in a research report issued on Tuesday. The firm presently has a “neutral” rating on the healthcare company’s stock. UBS Group’s target price indicates a potential upside of 6.80% from the stock’s current price.

A number of other research firms have also weighed in on ROG. Baader Bank set a CHF 256 target price on Roche and gave the stock a “buy” rating in a report on Tuesday, November 21st. Goldman Sachs Group set a CHF 325 target price on Roche and gave the stock a “buy” rating in a report on Thursday, December 7th. Barclays set a CHF 305 target price on Roche and gave the stock a “buy” rating in a report on Wednesday, December 27th. Berenberg Bank set a CHF 260 target price on Roche and gave the stock a “neutral” rating in a report on Tuesday, October 24th. Finally, DZ Bank set a CHF 270 target price on Roche and gave the stock a “buy” rating in a report on Friday, February 2nd. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of CHF 256.05.

Roche (VTX ROG) opened at CHF 221.90 on Tuesday. The firm has a market capitalization of $192,070.00 and a P/E ratio of 22.10. Roche has a 1-year low of CHF 214.30 and a 1-year high of CHF 273.

COPYRIGHT VIOLATION WARNING: “UBS Group Reiterates CHF 237 Price Target for Roche (ROG)” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/02/20/ubs-group-reiterates-chf-237-price-target-for-roche-rog.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply